Effects of helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Li, Wen Qing ^a,b   Ma, Jun Ling ^b   Zhang, Lian ^b   Brown, Linda M ^c   Li, Ji You ^b   Shen, Lin ^b   Pan, Kai Feng ^b   Liu, Wei Dong ^d   Hu, Yuanreng ^a   Han, Zhong Xiang ^d   Crystal Mansour, Susan ^e   Pee, David ^f   Blot, William J ^g,h   Fraumeni Jr , Joseph F ^a   You, Wei Cheng ^b   Gail, Mitchell H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c RTI INTERNATIONAL   (United States)

^d Linqu County Public Health Bureau   (China)

^e WESTAT   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^h VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; OMEPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; GASTROINTESTINAL DYSPLASIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER;

ADULT; AGE FACTORS; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OMEPRAZOLE; PRECANCEROUS CONDITIONS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84905241677     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju116     Document Type: Article

References (17)

1. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98(14):974-983.
2. Gail MH, Pfeiffer RM, Brown LM, et al. Garlic, vitamin, and antibiotic treatment for Helicobacter pylori: A randomized factorial controlled trial. Helicobacter. 2007;12(5):575-578.
3. Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials. 1998;19(4):352-369.
4. Ma JL, Zhang L, Brown LM, et al. Fifteenyear effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488-492.
5. Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev. 2011;7(1):59-64.
6. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer. 1999;83(5):615-619.
7. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993;53(6): 1317-1321.
8. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 2008;372(9636):392-397.
9. Morgan DR, Torres J, Sexton R, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309(6): 578-586.
10. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer prevention. Gut. 2013;62(5):676-682.
11. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical-trials. JAMA. 1991;266(1):93-98.
12. Forman D, Webb P, Parsonnet J. H pylori and gastric cancer. Lancet. 1994;343(8891): 243-244.
13. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA. 2004;291(2):187-194.
14. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21-29.
15. Tsai YC, Hsiao WH, Yang HB, et al. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther. 2013;37(10):969-978.
16. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631-636.
17. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011;17(41): 4596-4601